Qian Peng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Qian Peng has a total of 100 co-authors. Here are the top co-authors by number of shared publications:
Lei Zhong
Personalized Drug Therapy Key Laboratory of Sichuan Province, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, Chengdu 610072, Sichuan Province, China
3 shared publicationsLucia Clara Orlandini
Department of Radiation Oncology, Radiation Oncology Key Laboratory of Sichuan Province, Sichuan Cancer Hospital and Institute, Chengdu, China
3 shared publicationsBin Tang
Key Laboratory of Radiation Physics and Technology of the Ministry of Education, Institute of Nuclear Science and Technology, Sichuan University, Chengdu, China
2 shared publicationsGang Yin
Department of Radiation Oncology, Radiation Oncology Key Laboratory of Sichuan Province, Sichuan Cancer Hospital and Institute, Chengdu, China
2 shared publicationsJacopo Lenkowicz
Dipartimento Scienze Radiologiche, Fondazione Policlinico Universitario “A. Gemelli” IRCCS, Rome, Italy
2 shared publicationsJuan Xiao
2 shared publications
Latest Publications
- Open Access
- 20 October 2026
- Published by Elsevier in SSRN Electronic Journal
Safety and efficacy of modified sandwich neoadjuvant chemoradiotherapy followed by surgery and adjuvant chemotherapy for locally advanced rectal cancer: a prospective, single-arm, Phase II trial
Objective: This study evaluates the efficacy and safety of a modified sandwich (mSAND) neoadjuvant regimen combining 1.5T magnetic resonance guided linear accelerator (MR-Linac) guided short-course radiotherapy (SCRT; 25 Gy in 5 fractions) with sequential chemotherapy in patients with locally advanced rectal cancer (LARC).Methods: All patients received an mSAND neoadjuvant regimen. Tumor response was reassessed 2 weeks after neoadjuvant chemoradiotherapy (NCRT), followed by total mesorectal excision (TME) and six cycles of adjuvant mFOLFOX6. Primary endpoints were the rates of clinical complete response (cCR), pathological complete response (pCR), and objective response (ORR), secondary endpoints included 2-year overall survival (OS), locoregional recurrence-free survival (LRFS), progression-free survival (PFS), health-related quality of life (QoL), and treatment-related adverse events (TRAEs).Results: In this single-arm, phase II trial, 62 LARC patients were enrolled from December 2022 to October 2025, with a median follow-up of 15.5 months. The cCR rate was 22.6% ORR 61.3%, and pCR 25.8% (intention-to-treat). Following the mSAND regimen, both radiologic tumor regression and a significant decline in tumor biomarkers were observed (p < 0.05). At 2 years, LRFS, PFS, and OS rates were 79.9%, 78.3%, and 89.7%, respectively. Treatment was well-tolerated, with <2% Grade ≥3 gastrointestinal toxicity during NCRT and 6.5% Grade ≥3 hematologic toxicity during adjuvant chemotherapy. Quality-of-life scores (EORTC QLQ-C30) improved post-treatment steadily, reaching 87.8 at completion.Conclusion: The mSAND regimen demonstrated encouraging rates of cCR, pCR, and survival, with an acceptable safety profile.
- 20 October 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessSafety and efficacy of modified sandwich neoadjuvant chemoradiotherapy followed by surgery and adjuvant chemotherapy for locally advanced rectal cancer: a prospective, single-arm, Phase II trial
Objective: This study evaluates the efficacy and safety of a modified sandwich (mSAND) neoadjuvant regimen combining 1.5T magnetic resonance guided linear accelerator (MR-Linac) guided short-course radiotherapy (SCRT; 25 Gy in 5 fractions) with sequential chemotherapy in patients with locally advanced rectal cancer (LARC).Methods: All patients received an mSAND neoadjuvant regimen. Tumor response was reassessed 2 weeks after neoadjuvant chemoradiotherapy (NCRT), followed by total mesorectal excision (TME) and six cycles of adjuvant mFOLFOX6. Primary endpoints were the rates of clinical complete response (cCR), pathological complete response (pCR), and objective response (ORR), secondary endpoints included 2-year overall survival (OS), locoregional recurrence-free survival (LRFS), progression-free survival (PFS), health-related quality of life (QoL), and treatment-related adverse events (TRAEs).Results: In this single-arm, phase II trial, 62 LARC patients were enrolled from December 2022 to October 2025, with a median follow-up of 15.5 months. The cCR rate was 22.6% ORR 61.3%, and pCR 25.8% (intention-to-treat). Following the mSAND regimen, both radiologic tumor regression and a significant decline in tumor biomarkers were observed (p < 0.05). At 2 years, LRFS, PFS, and OS rates were 79.9%, 78.3%, and 89.7%, respectively. Treatment was well-tolerated, with <2% Grade ≥3 gastrointestinal toxicity during NCRT and 6.5% Grade ≥3 hematologic toxicity during adjuvant chemotherapy. Quality-of-life scores (EORTC QLQ-C30) improved post-treatment steadily, reaching 87.8 at completion.Conclusion: The mSAND regimen demonstrated encouraging rates of cCR, pCR, and survival, with an acceptable safety profile.
- Open Access
- 16 January 2024
- Published by Springer Nature in Physical and Engineering Sciences in Medicine
- Vol. 47 (1) , 351-359
Potential dosimetric error in the adaptive workflow of a 1.5 T MR-Linac from patient movement relative to immobilisation systems
In magnetic resonance- (MR-) based adaptive workflows for an MR-linac, the treatment plan is optimized and recalculated online using the daily MR images. The Unity MR-linac is supplied with a patient positioning device (ppd) using pelvic and abdomen thermoplastic masks attached to a board with high-density components. This study highlights the dosimetric effect of using this in such workflows when there are relative patient-ppd displacements, as these are not visualized on MR imaging and the treatment planning system assumes the patient is fixed relative to the ppd. The online adapted plans of two example rectum cancer patients treated at a Unity MR-linac were perturbed by introducing relative patient-ppd displacements, and the effect was evaluated on plan dosimetry. Forty-eight perturbed clinical adapted plans were recalculated, based on online MR-based synthetic computed tomography, and compared with the original plans, using dose-volume histogram parameters and gamma analysis. The target volume covered by the prescribed dose ( $${\text{D}}_{\text{p}\text{r}\text{e}}$$ ) and by at least 107% of $${\text{D}}_{\text{p}\text{r}\text{e}}$$ varied up to − 1.87% and + 3.67%, respectively for 0.5 cm displacements, and to − 3.18% and + 4.96% for 2 cm displacements; whilst 2%–2 mm gamma analysis showed a median value of 92.9%. The use of a patient positioning system with high-density components in a Unity MR-based online adaptive treatment workflow can introduce unrecognized errors in plan dosimetry and it is recommended not to use such a device for such treatments, without modifying the device and the workflow, followed by careful clinical evaluation, or alternatively to use other immobilization methods.- 16 January 2024
- Published by Springer Nature in Physical and Engineering Sciences in Medicine
- Vol. 47 (1) , 351-359
Open AccessPotential dosimetric error in the adaptive workflow of a 1.5 T MR-Linac from patient movement relative to immobilisation systems
In magnetic resonance- (MR-) based adaptive workflows for an MR-linac, the treatment plan is optimized and recalculated online using the daily MR images. The Unity MR-linac is supplied with a patient positioning device (ppd) using pelvic and abdomen thermoplastic masks attached to a board with high-density components. This study highlights the dosimetric effect of using this in such workflows when there are relative patient-ppd displacements, as these are not visualized on MR imaging and the treatment planning system assumes the patient is fixed relative to the ppd. The online adapted plans of two example rectum cancer patients treated at a Unity MR-linac were perturbed by introducing relative patient-ppd displacements, and the effect was evaluated on plan dosimetry. Forty-eight perturbed clinical adapted plans were recalculated, based on online MR-based synthetic computed tomography, and compared with the original plans, using dose-volume histogram parameters and gamma analysis. The target volume covered by the prescribed dose ( $${\text{D}}_{\text{p}\text{r}\text{e}}$$ ) and by at least 107% of $${\text{D}}_{\text{p}\text{r}\text{e}}$$ varied up to − 1.87% and + 3.67%, respectively for 0.5 cm displacements, and to − 3.18% and + 4.96% for 2 cm displacements; whilst 2%–2 mm gamma analysis showed a median value of 92.9%. The use of a patient positioning system with high-density components in a Unity MR-based online adaptive treatment workflow can introduce unrecognized errors in plan dosimetry and it is recommended not to use such a device for such treatments, without modifying the device and the workflow, followed by careful clinical evaluation, or alternatively to use other immobilization methods. - Open Access
- 15 August 2022
- Published by Baishideng Publishing Group Inc. in World Journal of Gastrointestinal Oncology
- Vol. 14 (8) , 1429-1445
Lymph node regression grading of locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy
Lymph node regression grading of locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy
- 15 August 2022
- Published by Baishideng Publishing Group Inc. in World Journal of Gastrointestinal Oncology
- Vol. 14 (8) , 1429-1445
Open AccessLymph node regression grading of locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy
Lymph node regression grading of locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy
- Open Access
- 15 April 2022
- Published by Springer Nature in Radiation Oncology
- Vol. 17 (1) , 1-8
Applicability of a pathological complete response magnetic resonance-based radiomics model for locally advanced rectal cancer in intercontinental cohort
Background: Predicting pathological complete response (pCR) in patients affected by locally advanced rectal cancer (LARC) who undergo neoadjuvant chemoradiotherapy (nCRT) is a challenging field of investigation, but many of the published models are burdened by a lack of reliable external validation. Aim of this study was to evaluate the applicability of a magnetic resonance imaging (MRI) radiomic-based pCR model developed and validated in Europe, to a different cohort of patients from an intercontinental cancer center. Methods: The original model was based on two clinical and two radiomics features extracted from T2-weighted 1.5 T MRI of 161 LARC patients acquired before nCRT, considered as training set. Such model is here validated using the T2-w 1.5 and 3 T staging MRI of 59 LARC patients with different clinical characteristics consecutively treated in mainland Chinese cancer center from March 2017 to January 2018. Model performance were evaluated in terms of area under the receiver operator characteristics curve (AUC) and relative parameters, such as accuracy, specificity, negative and positive predictive value (NPV and PPV). Results: An AUC of 0.83 (CI 95%, 0.71–0.96) was achieved for the intercontinental cohort versus a value of 0.75 (CI 95%, 0.61–0.88) at the external validation step reported in the original experience. Considering the best cut-off threshold identified in the first experience (0.26), the following predictive performance were obtained: 0.65 as accuracy, 0.64 as specificity, 0.70 as sensitivity, 0.91 as NPV and 0.28 as PPV. Conclusions: Despite the introduction of significant different factors, the proposed model appeared to be replicable on a real-world data extra-European patients’ cohort, achieving a TRIPOD 4 level.
- 15 April 2022
- Published by Springer Nature in Radiation Oncology
- Vol. 17 (1) , 1-8
Open AccessApplicability of a pathological complete response magnetic resonance-based radiomics model for locally advanced rectal cancer in intercontinental cohort
Background: Predicting pathological complete response (pCR) in patients affected by locally advanced rectal cancer (LARC) who undergo neoadjuvant chemoradiotherapy (nCRT) is a challenging field of investigation, but many of the published models are burdened by a lack of reliable external validation. Aim of this study was to evaluate the applicability of a magnetic resonance imaging (MRI) radiomic-based pCR model developed and validated in Europe, to a different cohort of patients from an intercontinental cancer center. Methods: The original model was based on two clinical and two radiomics features extracted from T2-weighted 1.5 T MRI of 161 LARC patients acquired before nCRT, considered as training set. Such model is here validated using the T2-w 1.5 and 3 T staging MRI of 59 LARC patients with different clinical characteristics consecutively treated in mainland Chinese cancer center from March 2017 to January 2018. Model performance were evaluated in terms of area under the receiver operator characteristics curve (AUC) and relative parameters, such as accuracy, specificity, negative and positive predictive value (NPV and PPV). Results: An AUC of 0.83 (CI 95%, 0.71–0.96) was achieved for the intercontinental cohort versus a value of 0.75 (CI 95%, 0.61–0.88) at the external validation step reported in the original experience. Considering the best cut-off threshold identified in the first experience (0.26), the following predictive performance were obtained: 0.65 as accuracy, 0.64 as specificity, 0.70 as sensitivity, 0.91 as NPV and 0.28 as PPV. Conclusions: Despite the introduction of significant different factors, the proposed model appeared to be replicable on a real-world data extra-European patients’ cohort, achieving a TRIPOD 4 level.
- Open Access
- 14 March 2022
- Published by Springer Nature in BMC Medical Imaging
- Vol. 22 (1) , 1-8
Local tuning of radiomics-based model for predicting pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer
Purpose: This study aims to further enhance a validated radiomics-based model for predicting pathologic complete response (pCR) after chemo‑radiotherapy in locally advanced rectal cancer (LARC) for use in clinical practice. Methods: A generalized linear model (GLM) to predict pCR in LARC patients previously trained in Europe and validated with an external inter-continental cohort (59 patients), was first examined with further 88 intercontinental patient datasets to assess its reproducibility; then new radiomics and clinical features, and validation methods were investigated to build a new model for enhancing the pCR prediction for patients admitted to our department. The patients were divided into training group (75%) and validation group (25%) according to their demographic. The least absolute shrinkage and selection operator (LASSO) logistic regression was used to reduce the dimensionality of the extracted features of the training group and select the optimal ones; the performance of the reference GLM and enhanced models was compared through the area under curve (AUC) of the receiver operating characteristics. Results: The value of AUC of the reference model was 0.831 (95% CI, 0.701–0.961), and 0.828 (95% CI, 0.700–0.956) in the original and new validation cohorts, respectively, showing a reproducibility in the applicability of the GLM model. Eight features were found to be significant with LASSO and used to establish an enhanced model. The AUC of the enhanced model of 0.926 (95% CI, 0.859–0.993) for training, and 0.926 (95% CI, 0.767–1.00) for the validation group shows better performance than the reference model. Conclusions: The GLM model shows good reproducibility in predicting pCR in LARC; the enhanced model has the potential to improve prediction accuracy and may be a candidate in clinical practice.
- 14 March 2022
- Published by Springer Nature in BMC Medical Imaging
- Vol. 22 (1) , 1-8
Open AccessLocal tuning of radiomics-based model for predicting pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer
Purpose: This study aims to further enhance a validated radiomics-based model for predicting pathologic complete response (pCR) after chemo‑radiotherapy in locally advanced rectal cancer (LARC) for use in clinical practice. Methods: A generalized linear model (GLM) to predict pCR in LARC patients previously trained in Europe and validated with an external inter-continental cohort (59 patients), was first examined with further 88 intercontinental patient datasets to assess its reproducibility; then new radiomics and clinical features, and validation methods were investigated to build a new model for enhancing the pCR prediction for patients admitted to our department. The patients were divided into training group (75%) and validation group (25%) according to their demographic. The least absolute shrinkage and selection operator (LASSO) logistic regression was used to reduce the dimensionality of the extracted features of the training group and select the optimal ones; the performance of the reference GLM and enhanced models was compared through the area under curve (AUC) of the receiver operating characteristics. Results: The value of AUC of the reference model was 0.831 (95% CI, 0.701–0.961), and 0.828 (95% CI, 0.700–0.956) in the original and new validation cohorts, respectively, showing a reproducibility in the applicability of the GLM model. Eight features were found to be significant with LASSO and used to establish an enhanced model. The AUC of the enhanced model of 0.926 (95% CI, 0.859–0.993) for training, and 0.926 (95% CI, 0.767–1.00) for the validation group shows better performance than the reference model. Conclusions: The GLM model shows good reproducibility in predicting pCR in LARC; the enhanced model has the potential to improve prediction accuracy and may be a candidate in clinical practice.
- Open Access
- 4 February 2022
- Published by Springer Nature in Research Square
Local Tuning of Radiomics-Based Model for Predicting Pathological Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer
Purpose: This study aims to further enhance a validated radiomics-based model for predicting pathologic complete response (pCR) after chemo‑radiotherapy in locally advanced rectal cancer (LARC) for use in the clinical practice. Methods: A generalized linear model (GLM) to predict pCR in LARC patients previously trained in Europe and validated with external inter-continental cohort (59 patients) was first examined with further 88 intercontinental patient datasets to assess its reproducibility; new radiomics and clinical features, and validation methods were aslo investigated to enhance the pCR prediction for patients admitted to our department. The patients were divided into training group (75%) and validation group (25%) according to their demographic. The least absolute shrinkage and selection operator (LASSO) logistic regression was used to reduce the dimensionality of the extracted features of the training group and select the optimal ones; the performance of the reference GLM and enhanced models was compared through the area under curve (AUC) of the receiver operating characteristics. Results: The value of AUC of the reference model was 0.831 (95% CI, 0.701‐0.961), and 0.828 (95% CI, 0.700 ‐0.956) in the original and new validation cohorts, respectively, showing a reproducibility in the applicability of the original model. Eight features were found to be significant with LASSO model and added in the new model. The AUC of the enhanced model of 0.926 (95% CI, 0.859-0.993) for training, and 0.926 (95% CI, 0.767-1.00) for the validation group shows better performance than the reference model. Conclusions: the GLM model shows a good reproducibility in predicting pCR in LARC; the enhanced model has the potential to improve prediction accuracy and may be a candidate in clinical practice.
- 4 February 2022
- Published by Springer Nature in Research Square
Open AccessLocal Tuning of Radiomics-Based Model for Predicting Pathological Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer
Purpose: This study aims to further enhance a validated radiomics-based model for predicting pathologic complete response (pCR) after chemo‑radiotherapy in locally advanced rectal cancer (LARC) for use in the clinical practice. Methods: A generalized linear model (GLM) to predict pCR in LARC patients previously trained in Europe and validated with external inter-continental cohort (59 patients) was first examined with further 88 intercontinental patient datasets to assess its reproducibility; new radiomics and clinical features, and validation methods were aslo investigated to enhance the pCR prediction for patients admitted to our department. The patients were divided into training group (75%) and validation group (25%) according to their demographic. The least absolute shrinkage and selection operator (LASSO) logistic regression was used to reduce the dimensionality of the extracted features of the training group and select the optimal ones; the performance of the reference GLM and enhanced models was compared through the area under curve (AUC) of the receiver operating characteristics. Results: The value of AUC of the reference model was 0.831 (95% CI, 0.701‐0.961), and 0.828 (95% CI, 0.700 ‐0.956) in the original and new validation cohorts, respectively, showing a reproducibility in the applicability of the original model. Eight features were found to be significant with LASSO model and added in the new model. The AUC of the enhanced model of 0.926 (95% CI, 0.859-0.993) for training, and 0.926 (95% CI, 0.767-1.00) for the validation group shows better performance than the reference model. Conclusions: the GLM model shows a good reproducibility in predicting pCR in LARC; the enhanced model has the potential to improve prediction accuracy and may be a candidate in clinical practice.
- Open Access
- 7 May 2020
- Published by Springer Nature in Radiation Oncology
- Vol. 15 (1) , 1-7
Impact of positioning errors in the dosimetry of VMAT left-sided post mastectomy irradiation
Background: Volumetric modulated arc therapy (VMAT) adopted in post-mastectomy radiation therapy (PMRT) has the capacity to achieve highly conformal dose distributions. The research aims to evaluate the impact of positioning errors in the dosimetry of VMAT left-sided PMRT. Methods: A total of 18 perturbations where introduced in 11 VMAT treatment plans that shifted the isocenter from its reference position of 3, 5, 10 mm in six directions. The thoracic wall and supraclavicular clinical target volumes (CTVs), the heart and the left lung dose volume histograms (DVHs) of 198 perturbed plans were calculated. The absolute differences (∆) of the mean dose (Dm) and DVH endpoints Vx and Dy (percentage volume receiving x Gy, and dose covering y% of the volume, respectively) were used to compare the dosimetry of the reference vs perturbed plans. Results: Isocenter shifts in the anterior and lateral directions lead to maximum disagreement between the CTVs dosimetry of perturbed vs reference plans. Isocenter shifts of 10 mm shown a decrease of D95, D98 and Dm of 12.8, 18.0, and 2.9% respectively, for the CTVs. For 5 mm isocenter shifts, these differences decreased to 3.2, 5.2, and 0.9%, respectively, and for 3 mm shifts to 1.0, 1.7, and 0.6%, respectively. For the organs at risk (OARs), only isocenter shifts in the right, posterior and inferior directions worsen the plan dosimetry, nevertheless not negligible lung ∆ V20 of + 2.6%, and heart ∆ V25 of + 1.6% persist for 3 mm shifts. Conclusions: Inaccuracy in isocenter positioning for VMAT left-sided PMRT irradiation may impact the dosimetry of the CTVs and OARs to a different extent, depending on the directions and magnitude of the perturbation. The acquired information could be useful for planning strategies to guarantee the accuracy of the treatment delivered.
- 7 May 2020
- Published by Springer Nature in Radiation Oncology
- Vol. 15 (1) , 1-7
Open AccessImpact of positioning errors in the dosimetry of VMAT left-sided post mastectomy irradiation
Background: Volumetric modulated arc therapy (VMAT) adopted in post-mastectomy radiation therapy (PMRT) has the capacity to achieve highly conformal dose distributions. The research aims to evaluate the impact of positioning errors in the dosimetry of VMAT left-sided PMRT. Methods: A total of 18 perturbations where introduced in 11 VMAT treatment plans that shifted the isocenter from its reference position of 3, 5, 10 mm in six directions. The thoracic wall and supraclavicular clinical target volumes (CTVs), the heart and the left lung dose volume histograms (DVHs) of 198 perturbed plans were calculated. The absolute differences (∆) of the mean dose (Dm) and DVH endpoints Vx and Dy (percentage volume receiving x Gy, and dose covering y% of the volume, respectively) were used to compare the dosimetry of the reference vs perturbed plans. Results: Isocenter shifts in the anterior and lateral directions lead to maximum disagreement between the CTVs dosimetry of perturbed vs reference plans. Isocenter shifts of 10 mm shown a decrease of D95, D98 and Dm of 12.8, 18.0, and 2.9% respectively, for the CTVs. For 5 mm isocenter shifts, these differences decreased to 3.2, 5.2, and 0.9%, respectively, and for 3 mm shifts to 1.0, 1.7, and 0.6%, respectively. For the organs at risk (OARs), only isocenter shifts in the right, posterior and inferior directions worsen the plan dosimetry, nevertheless not negligible lung ∆ V20 of + 2.6%, and heart ∆ V25 of + 1.6% persist for 3 mm shifts. Conclusions: Inaccuracy in isocenter positioning for VMAT left-sided PMRT irradiation may impact the dosimetry of the CTVs and OARs to a different extent, depending on the directions and magnitude of the perturbation. The acquired information could be useful for planning strategies to guarantee the accuracy of the treatment delivered.
- 1 January 2019
- Published by Elsevier in Differentiation
- Vol. 105, 33-44
Connexin 43 is involved in early differentiation of human embryonic stem cells
- 1 January 2019
- Published by Elsevier in Differentiation
- Vol. 105, 33-44
Connexin 43 is involved in early differentiation of human embryonic stem cells
- 15 August 2018
- Published by Springer Nature in Investigational New Drugs
- Vol. 37 (4) , 616-624
Preclinical assessment of histone deacetylase inhibitor quisinostat as a therapeutic agent against esophageal squamous cell carcinoma
Esophageal squamous cell carcinoma (ESCC) is one of the most serious life-threatening malignancies. Although chemotherapeutic targets and agents for ESCC have made much progress recently, the efficacy is still unsatisfactory. Therefore, there is still an unmet medical need for patients with ESCC. Here, we report the expression status of HDAC1 in human ESCC and matched paracancerous tissues, and the results indicated that HDAC1 was generally upregulated in ESCC specimens. Furthermore, we comprehensively assessed the anti-ESCC activity of a highly active HDAC1 inhibitor quisinostat. Quisinostat could effectively suppress cellular viability and proliferation of ESCC cells, as well as induce cell cycle arrest and apoptosis even at low treatment concentrations. The effectiveness was also observed in KYSE150 xenograft model when quisinostat was administered at tolerated doses (3 mg/kg and 10 mg/kg). Meanwhile, quisinostat also had the ability to suppress the migration and invasion (pivotal steps of tumor metastasis) of ESCC cells. Western blot analysis indicated that quisinostat exerted its anti-ESCC effects mainly through blockade of Akt/mTOR and MAPK/ERK signaling cascades. Overall, HDAC1 may serve as a potential therapeutic target for ESCC, and quisinostat deserves to be further assessed as a promising drug candidate for the treatment of ESCC.
- 15 August 2018
- Published by Springer Nature in Investigational New Drugs
- Vol. 37 (4) , 616-624
Preclinical assessment of histone deacetylase inhibitor quisinostat as a therapeutic agent against esophageal squamous cell carcinoma
Esophageal squamous cell carcinoma (ESCC) is one of the most serious life-threatening malignancies. Although chemotherapeutic targets and agents for ESCC have made much progress recently, the efficacy is still unsatisfactory. Therefore, there is still an unmet medical need for patients with ESCC. Here, we report the expression status of HDAC1 in human ESCC and matched paracancerous tissues, and the results indicated that HDAC1 was generally upregulated in ESCC specimens. Furthermore, we comprehensively assessed the anti-ESCC activity of a highly active HDAC1 inhibitor quisinostat. Quisinostat could effectively suppress cellular viability and proliferation of ESCC cells, as well as induce cell cycle arrest and apoptosis even at low treatment concentrations. The effectiveness was also observed in KYSE150 xenograft model when quisinostat was administered at tolerated doses (3 mg/kg and 10 mg/kg). Meanwhile, quisinostat also had the ability to suppress the migration and invasion (pivotal steps of tumor metastasis) of ESCC cells. Western blot analysis indicated that quisinostat exerted its anti-ESCC effects mainly through blockade of Akt/mTOR and MAPK/ERK signaling cascades. Overall, HDAC1 may serve as a potential therapeutic target for ESCC, and quisinostat deserves to be further assessed as a promising drug candidate for the treatment of ESCC.
- Open Access
- 27 July 2018
- Published by Impact Journals, LLC in Oncotarget
- Vol. 9 (58) , 31291-31301
Relevance of methylenetetrahydrofolate reductase gene variants C677T and A1298C with response to fluoropyrimidine-based chemotherapy in colorectal cancer: a systematic review and meta-analysis
Relevance of methylenetetrahydrofolate reductase gene variants C677T and A1298C with response to fluoropyrimidine-based chemotherapy in colorectal cancer: a systematic review and meta-analysis Relevance of methylenetetrahydrofolate reductase gene variants C677T and A1298C with response to fluoropyrimidine-based chemotherapy in colorectal cancer: a systematic review and meta-analysis
- 27 July 2018
- Published by Impact Journals, LLC in Oncotarget
- Vol. 9 (58) , 31291-31301
Open AccessRelevance of methylenetetrahydrofolate reductase gene variants C677T and A1298C with response to fluoropyrimidine-based chemotherapy in colorectal cancer: a systematic review and meta-analysis
Relevance of methylenetetrahydrofolate reductase gene variants C677T and A1298C with response to fluoropyrimidine-based chemotherapy in colorectal cancer: a systematic review and meta-analysis Relevance of methylenetetrahydrofolate reductase gene variants C677T and A1298C with response to fluoropyrimidine-based chemotherapy in colorectal cancer: a systematic review and meta-analysis